CD274 and neoplasm: The programmed cell death (PD)‐1 pathway has become an attractive therapeutic target in multiple cancers.16, 17 Blocking the interaction between PD‐1 and its ligands, PD‐L1 and PD‐L2, leads to impressive antitumor responses and clinical benefit in a subset of patients,18, 19 including relapsed and refractory DLBCL.20, 21 However, predicting tumor responses to PD‐1 blockade remains a major challenge.